The Supreme Court examines steep mark-ups on cancer drugs and questions why prices vary sharply across the medicine supply chain, raising concerns about who benefits from inflated costs. In court, it hears arguments that the resulting price disparities make essential cancer medicines less affordable for patients.
Petitioners ask the apex court to intervene to regulate the pricing of drugs, medical equipment, and generic medicines. Multiple reports say they highlight the “pricing disparity” across different stages—from importers and wholesalers to retailers—and argue that existing mechanisms have allowed large increases before medicines reach end users. BusinessLine reports that the court focuses on how such mark-ups arise and who ultimately benefits, while The Hindu notes the petitioners’ broader request for affordability-focused regulation.
Overall, the coverage indicates the court is probing pricing structures and possible regulatory gaps, as petitioners seek directions aimed at narrowing price differences for cancer therapies and other healthcare products, including generics.
